# Beijing InnoCare Pharma Tech Co., Ltd. trials: 61 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 61 trials with Beijing InnoCare Pharma Tech Co., Ltd. as lead sponsor, 27 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Beijing InnoCare Pharma Tech Co., Ltd.: 61 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 61
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 61, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925190 | A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Recruiting | Acute Myeloblastic Leukemia | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925190) |
| November 3, 2026 | NCT07911982 | Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteers | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 | Not yet recruiting | Inflammatory Bowel Disease(IBD) | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911982) |
| October 28, 2026 | NCT07901413 | Evaluation of ICP-B381 in Patients With Advanced Solid Tumors | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901413) |
| October 27, 2026 | NCT07896590 | Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed/Refractory Marginal Zone Lymphoma (MZL) | 292 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896590) |
| August 25, 2026 | NCT07784101 | A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or... | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784101) |
| July 27, 2026 | NCT07727486 | A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 | Not yet recruiting | Primary Sjögren's Syndrome | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727486) |
| June 1, 2026 | NCT07617493 | Evaluation of ICP-B208 in Patients With Advanced Solid Tumors | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 551 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617493) |
| April 16, 2026 | NCT07535099 | Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 | Recruiting | Health Services Research | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535099) |
| February 27, 2026 | NCT07440537 | Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 | Recruiting | Cutaneous Lupus Erythematosus (CLE) | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07440537) |
| January 30, 2026 | NCT07378527 | Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2/3 | Recruiting | Chronic Spontaneous Urticaria (CSU) | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07378527) |
| November 26, 2025 | NCT07251998 | Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 | Completed | Plaque Psoriasis | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07251998) |
| November 19, 2025 | NCT07236099 | Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 | Recruiting | Prurigo Nodularis (PN) | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236099) |
| August 22, 2025 | NCT07136558 | Evaluation of ICP-B794 in Patients With Advanced Solid Tumors | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 | Not yet recruiting | Advanced Solid Tumors | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136558) |
| July 24, 2025 | NCT07082686 | A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 | Recruiting | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07082686) |
| July 2, 2025 | NCT07047612 | ICP-332 in Subjects With Non-segmental Vitiligo | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2/3 | Recruiting | Non Segmental Vitiligo | 603 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047612) |
| February 25, 2025 | NCT06845241 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Non-Hodgkin Lymphoma | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06845241) |
| February 24, 2025 | NCT06842199 | Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Recruiting | Plaque Psoriasis Patients | 383 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06842199) |
| January 15, 2025 | NCT06775860 | ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Recruiting | Atopic Dermatitis | 552 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06775860) |
| October 24, 2024 | NCT06656494 | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 | Recruiting | Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS) | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06656494) |
| July 25, 2024 | NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in... | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Recruiting | DLBCL | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06521255) |
| April 22, 2024 | NCT06378138 | ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2/3 | Recruiting | Hematologic Malignancies | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06378138) |
| October 31, 2023 | NCT06109818 | Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 | Completed | Moderate to Severe Plaque Psoriasis | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06109818) |
| October 13, 2023 | NCT06082102 | Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With... | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Recruiting | Relapsed/Refractory Marginal Zone Lymphoma | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06082102) |
| August 22, 2023 | NCT06004856 | Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Unknown | Chronic Primary Immune Thrombocytopenia (ITP) | 195 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06004856) |
| February 27, 2023 | NCT05745623 | Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05745623) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 14 |
| Phase 2 | 18 |
| Phase 2/3 | 3 |
| Phase 3 | 11 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 21 |
| Unknown | 20 |
| Completed | 12 |
| Not yet recruiting | 6 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Recurrence | 5 |
| Lymphoma, Mantle-Cell | 3 |
| Hematologic Neoplasms | 3 |
| Cholangiocarcinoma | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Lymphoma, B-Cell, Marginal Zone | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Inflammatory Bowel Diseases | 1 |
| Carcinoma, Transitional Cell | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Psoriasis | 1 |
| Multiple Sclerosis, Relapsing-Remitting | 1 |
| Chronic Urticaria | 1 |
| Myelodysplastic Syndromes | 1 |
| Lupus Erythematosus, Cutaneous | 1 |
| Purpura, Thrombocytopenic, Idiopathic | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Hematoma | 1 |
| Dermatitis, Atopic | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Closet remodeling companies in the United States](https://specstream.ai/data/businesses/closet-remodeling-companies/united-states)
- [Theme restaurants in the United States](https://specstream.ai/data/businesses/theme-restaurants/united-states)
- [Meat wholesalers in the United States](https://specstream.ai/data/businesses/meat-wholesalers/united-states)
- [Dermatology practices in the United States](https://specstream.ai/data/businesses/dermatology-practices/united-states)
- [Waste collection companies in the United States](https://specstream.ai/data/businesses/waste-collection-companies/united-states)
- [Office cleaning companies in the United States](https://specstream.ai/data/businesses/office-cleaning-companies/united-states)
